Compare Fox Corp Class B (FOX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Johnson & Johnson — how do they compare? Fox Corp Class B trades at $55.89 (market cap $25.36B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 24.4× Fox Corp Class B's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Johnson & Johnson for 129 Days on average.
| FOX | JNJ | |
|---|---|---|
Market Cap | $25.36B | $618.09B |
Volume | 886,620 | 6,050,983 |
Sector | Media | Health |
52-Week High | $67.76 | $278.43 |
52-Week Low | $44.39 | $186.00 |
Typical Hold Time | 75 Days | 129 Days |
Enterprise Value | $28.72B | $646.37B |
Dividend Yield | 1.02% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.97, up 1.77% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $16.30B in 2025, with net income reaching $2.26B and a profit margin of 13.88%. The stock is supported by positive analyst sentiment, with a consensus price target of $84.75, indicating significant upside potential from current levels.
The outlook for FOX is favorable, driven by robust profitability and valuation metrics below industry averages. Key risks include a projected decline in 2026 net income and ongoing regulatory scrutiny of acquisitions. The stock presents a compelling opportunity for value-oriented investors, though monitoring execution on future earnings is critical.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
